Skip to main content

Post Menopausal Osteoporosis

9
Pipeline Programs
6
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
3
5
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
7 programs
3
4
IbandronatePhase 41 trial
RisedronatePhase 41 trial
ibandronate [Bonviva/Boniva]Phase 41 trial
ibandronate [Bonviva/Boniva]Phase 41 trial
Ibandronate [Bonviva/Boniva]Phase 31 trial
+2 more programs
Active Trials
NCT00048061Completed1,609Est. Dec 2004
NCT00048074Completed1,395Est. May 2005
NCT01290094Completed41Est. Jul 2014
+4 more trials
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
ibandronate [Bonviva/Boniva]Phase 4
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
Abaloparatide TransdermalPhase 2
Amgen
AmgenTHOUSAND OAKS, CA
1 program
AMG 162 - ProliaN/A1 trial
Active Trials
NCT02347865Completed777Est. Sep 2018
Radius Health
Radius HealthMA - Boston
1 program
Abaloparatide TransdermalPHASE_21 trial
Active Trials
NCT01674621Completed250Est. Aug 2013
GSK
GSKLONDON, United Kingdom
1 program
ibandronate [Bonviva/Boniva]PHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Genentechibandronate [Bonviva/Boniva]
Genentechibandronate [Bonviva/Boniva]
GenentechRisedronate
GenentechIbandronate
Genentechibandronate [Bonviva/Boniva]
Genentechibandronate [Bonviva/Boniva]
GenentechIbandronate [Bonviva/Boniva]
Radius HealthAbaloparatide Transdermal
AmgenAMG 162 - Prolia

Clinical Trials (9)

Total enrollment: 5,893 patients across 9 trials

NCT00545090Genentechibandronate [Bonviva/Boniva]

ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

Start: Aug 2006Est. completion: Jun 2008561 patients
Phase 4Completed
NCT00545480Genentechibandronate [Bonviva/Boniva]

SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.

Start: Jul 2006Est. completion: Mar 2009596 patients
Phase 4Completed
NCT00377234GenentechRisedronate

A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.

Start: May 2006Est. completion: Aug 2008356 patients
Phase 4Completed
NCT02598934GenentechIbandronate

A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

Start: Aug 2004Est. completion: May 2006308 patients
Phase 4Completed
NCT01290094Genentechibandronate [Bonviva/Boniva]

A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis

Start: Apr 2011Est. completion: Jul 201441 patients
Phase 3Completed
NCT00048074Genentechibandronate [Bonviva/Boniva]

DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis

Start: Jun 2002Est. completion: May 20051,395 patients
Phase 3Completed
NCT00048061GenentechIbandronate [Bonviva/Boniva]

MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

Start: Apr 2002Est. completion: Dec 20041,609 patients
Phase 3Completed
NCT01674621Radius HealthAbaloparatide Transdermal

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

Start: Sep 2012Est. completion: Aug 2013250 patients
Phase 2Completed
NCT02347865AmgenAMG 162 - Prolia

Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France

Start: Jun 2015Est. completion: Sep 2018777 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.